Who Paid My Doc
Robin McKelvey
Internal Medicine Corvallis, OR Medical Doctor
NPI 1730228727 CMS profile 33811
3680 Nw Samaritan Dr, Corvallis, OR 97330
General payments
$17,620
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$788,171
Through program year 2024, Robin McKelvey of Corvallis, OR is reported in the CMS Open Payments database as having received $17,620 across 38 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $788,171 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $1,365 | 8 | |
| 2022 | General | $24 | 1 | |
| 2019 | General | $16,231 | 29 |
Beside peers
- Robin McKelvey
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Robin McKelvey were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Robin McKelvey | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $16,231 | $159 | $48–$570 | $163 |
| 2020 | $0 | $119 | $33–$402 | $114 |
| 2021 | $0 | $135 | $37–$521 | $132 |
| 2022 | $24 | $141 | $42–$496 | $149 |
| 2023 | $0 | $149 | $45–$519 | $160 |
| 2024 | $1,365 | $154 | $47–$537 | $164 |
| 2025 | $0 | $156 | $47–$551 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 147 drugsPart D claims
7,835
Drug cost
$651,975
Branded share of claims
20.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 93 | $121,724 | |
| Eliquis Apixaban | Brand | 109 | $115,860 | |
| Jardiance Empagliflozin | Brand | 49 | $65,700 | |
| Xarelto Rivaroxaban | Brand | 32 | $36,457 | |
| Mounjaro Tirzepatide | Brand | 26 | $26,611 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 12 | $24,667 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 27 | $22,231 | |
| Isentress Raltegravir Potassium | Brand | 12 | $22,112 | |
| Trulicity Dulaglutide | Brand | 21 | $18,633 | |
| Rybelsus Semaglutide | Brand | 12 | $16,979 |
The 10 drugs with the highest cost, of 147 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 77 billing codesPaid by Medicare
$36,786
Medicare patients
228
Services billed
1,230
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Arthritis | 39% | |
| Diabetes | 26% | |
| Depression | 22% | |
| Atrial fibrillation | 19% | |
| Osteoporosis | 16% | |
| Ischemic heart disease | 11% | |
| Chronic kidney disease | 11% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Pcv20 vaccine im 90677 | Office | 11 | 11 | $3,176 |
| Sarscv2 vac 30mcg trs-suc im 91320 | Office | 18 | 18 | $2,531 |
| Vaccine for influenza for injection into muscle 90653 | Office | 15 | 15 | $1,227 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
38 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in Oregon
Related records
Internal Medicine in Oregon
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Oregon
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.